Literature DB >> 21430453

P21 Ser31Arg polymorphism and cervical cancer risk: a meta-analysis.

Ya Li1, Fei Liu, Shiqiao Tan, Shangwei Li.   

Abstract

BACKGROUND: Studies investigating the association between p21 genetic polymorphism Ser31Arg and cervical cancer (CC) risk report conflicting results. The aim of this study was to quantitatively summarize the evidence for p21 polymorphism and CC risk.
METHODS: Two investigators independently searched the MEDLINE, Embase, CNKI, and Chinese Biomedicine databases. Summary odds ratios (ORs) and 95% confidence intervals (CIs) for p21 polymorphism and CC were calculated in a fixed effects model (the Mantel-Haenszel method) and a random effects model (the DerSimonian and Laird method) when appropriate. The pooled ORs were performed for codominant model (Arg/Arg vs Ser/Ser and Arg/Ser vs Ser/Ser), dominant model (Arg/Arg + Arg/Ser vs Ser/Ser), and recessive model (Arg/Arg vs Arg/Ser + Ser/Ser). Subgroup analyses were performed by country, matched controls, and Hardy-Weinberg equilibrium in the controls and study sample size.
RESULTS: This meta-analysis included 10 case-control studies from an Asian population, which included 1415 CC cases and 1947 controls. Overall, the variant genotypes (Arg/Arg and Arg/Ser) of Ser31Arg were not associated with CC risk, when compared with the wild-type homozygote Ser/Ser (Arg/Arg vs Ser/Ser: OR, 1.30; 95% CI, 0.81-2.08; Arg/Ser vs Ser/Ser: OR, 1.06; 95% CI, 0.72-1.55). Similarly, no associations were found in the dominant and recessive models (dominant model: OR, 1.05; 95% CI, 0.73-1.51; recessive model: OR, 1.28; 95% CI, 0.86-1.90). Stratified analyses also detected no significant association in any subgroup, except among those studies from "other" country and those studies with controls deviated from Hardy-Weinberg equilibrium.
CONCLUSION: No association was found between the p21 polymorphism Arg31Ser and risk of CC among Asians. In the future, additional studies based on white and African American patients should be performed to re-evaluate the association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21430453     DOI: 10.1097/IGC.0b013e31820da58b

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  MTHFR C677T and A1298C polymorphisms and cervical carcinoma susceptibility: meta-analyses based on 4,421 individuals.

Authors:  Wen-Lei Zhuo; Liang Zhang; Jun-Jun Ling; Yi Zhu; Zheng-Tang Chen
Journal:  Mol Biol Rep       Date:  2012-06-19       Impact factor: 2.316

2.  The 46359CT polymorphism of DNMT3B is associated with the risk of cervical cancer.

Authors:  Daniel Hernández-Sotelo; Rubén García-Aguilar; Yaneth Castro-Coronel; Jonathan J Magaña; Marco Antonio Leyva-Vazquez; Luz del Carmen Alarcón-Romero; Esther López-Bayghen; Berenice Illades-Aguiar
Journal:  Mol Biol Rep       Date:  2013-05-16       Impact factor: 2.316

Review 3.  Genetic susceptibility to cervical cancer: role of common polymorphisms in apoptosis-related genes.

Authors:  Shing Cheng Tan; Ravindran Ankathil
Journal:  Tumour Biol       Date:  2015-08-05

4.  Association Between p21 Ser31Arg Polymorphism and Gastrointestinal Tract Tumor Risk: A Meta-analysis.

Authors:  Ying Dong; Xiaohua Wang; Xiaofeng Ye; Guanhua Wang; Yan Li; Ningju Wang; Yinxue Yang; Zhiqiang Chen; Wenjun Yang
Journal:  Technol Cancer Res Treat       Date:  2014-11-24

Review 5.  Cervical Cancer Genetic Susceptibility: A Systematic Review and Meta-Analyses of Recent Evidence.

Authors:  Gabriela A Martínez-Nava; Julián A Fernández-Niño; Vicente Madrid-Marina; Kirvis Torres-Poveda
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

6.  Association between tobacco substance usage and a missense mutation in the tumor suppressor gene P53 in the Saudi Arabian population.

Authors:  Mikhlid H Almutairi; Bader O Almutairi; Turki M Alrubie; Sultan N Alharbi; Narasimha R Parine; Abdulwahed F Alrefaei; Ibrahim Aldeailej; Abdullah Alamri; Abdelhabib Semlali
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.